Published : Nov-2021
No. of Pages : 131
1 Migraine: Executive Summary
1.1 Migraine Therapeutics Market will grow to $12.0B
1.2 Key Players Will Maintain Their Competitive Position
1.3 Access to Effective and Tolerable Prophylactic Treatments and Additional Acute Therapy Options Remain Unmet Needs
1.4 The Gepants Are the Most Promising New Entrants to the Migraine Market
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
3.2.1 Premonitory Phase
3.2.2 Aura Phase
3.2.3 Headache Phase
3.2.4 Resolution Phase
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 7MM Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine
4.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine by Frequency
4.4.5 12-Month Total Prevalent Cases of Migraine by Type
4.4.6 12-Month Diagnosed Prevalent Cases of Migraine
4.5 Epidemiological Forecast for Migraine (2020-2030)
4.5.1 12-Month Total Prevalent Cases of Migraine
4.5.2 Age-Specific 12-Month Total Prevalent Cases of Migraine
4.5.3 Sex-Specific 12-Month Total Prevalent Cases of Migraine
4.5.4 12-Month Total Prevalent Cases of Migraine by Frequency of Episodic and Chronic
4.5.5 12-Month Total Prevalent Cases of Migraine by Type
4.5.6 12-Month Diagnosed Prevalent Cases of Migraine
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of the Analysis
4.6.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Episodic Migraine
5.1.2 Chronic Migraine
5.2 Additional KOL Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders
7.3 Limited Acute Therapies for Patients Unresponsive to Triptan Medication
7.4 Access to Effective and Tolerable Prophylactic Treatments
7.5 Physician Education for Diagnosis
7.6 Raise Awareness of the Disease in the General Population
8 R&D Strategies
8.1 Overview
8.1.1 Gepants for Dual-Acting Acute and Preventive Indications
8.1.2 Preventive Drugs with Long Duration of Action
8.1.3 Improving Efficacy of Marketed Migraine Drugs
8.1.4 Novel MOAs
8.2 Clinical Trials Design
8.2.1 Study Design
8.2.2 Endpoints for Migraine Clinical Trials
8.2.3 Patient Recruitment
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
10.2.1 Acute Treatment for Migraine
10.2.2 Preventive Treatment for Migraine
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting Methodology
13.4 Primary Research - KOLs Interviewed for This Report
13.4.1 KOLs
13.5 Primary Research - Prescriber Survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Managing Analyst
13.6.3 Therapy Area Director
13.6.4 Epidemiologist
13.6.5 Managing Epidemiologist
13.6.6 Global Director of Therapy Analysis and Epidemiology
13.6.7 Global Head and EVP of Healthcare Operations and Strategy
Contact Us
List of Tables
Table 1: Disease Migraine: Key Metrics in the 7MM
Table 2: Migraine Classification from the ICHD-3
Table 3: Diagnostic Criteria for Migraine with Aura
Table 4: Diagnostic Criteria for Migraine without Aura
Table 5: Risk Factors and Comorbidities for Migraine
Table 6: Treatment Guidelines for Disease Migraine
Table 7: Most Prescribed Drugs for Migraine by Class in the 7MM
Table 8: Migraine Market - Global Drivers and Barriers, 2020-2030
Table 9: Key Events Impacting Sales for Migraine in the US, 2020-2030
Table 10: Migraine Market - Drivers and Barriers in the US, 2020-2030
Table 11: Key Events Impacting Sales for Migraine in the 5EU, 2020-2030
Table 12: Migraine Market - Drivers and Barriers in the 5EU, 2020-2030
Table 13: Key Events Impacting Sales for Migraine in Japan, 2020-2030
Table 14: Migraine Market - Drivers and Barriers in Japan, 2020- 2030
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Migraine in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period
Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.
Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.
Figure 5: Pathophysiology of a Migraine
Figure 6: 7MM, 12-Month Total Prevalence of Migraine, Men and Women, %, Ages ?18 Years, 2020
Figure 7: 7MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of Migraine
Figure 8: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Frequency
Figure 9: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Type
Figure 10: 7MM, Sources Used to Forecast the Diagnosis Rate of Migraine
Figure 11: 7MM, 12-Month Total Prevalent Cases of Migraine, N, Both Sexes, Ages ?18 Years, 2020
Figure 12: 7MM, 12-Month Total Prevalent Cases of Migraine by Age, N, Both Sexes, 2020
Figure 13: 7MM, 12-Month Total Prevalent Cases of Migraine by Sex, N, Ages ?18 Years, 2020
Figure 14: 7MM, 12-Month Total Prevalent Cases of Migraine by Frequency, N, Both Sexes, Ages ?18 Years, 2020
Figure 15: 7MM, 12-Month Total Prevalent Cases of Migraine by Type, N, Both Sexes, Ages ?18 Years, 2020
Figure 16: 7MM, 12-Month Diagnosed Prevalent Cases of Migraine, N, Both Sexes, Ages ?18 Years, 2020
Figure 17: Unmet Needs and Opportunities in Migraine
Figure 18: Overview of the Development Pipeline in Migraine
Figure 19: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Migraine in the 7MM During the Forecast Period
Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.
Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.
Figure 22: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period
Figure 23: Global (7MM) Sales Forecast by Country for Migraine in 2020 and 2030
Figure 24: Global (7MM) Sales Forecast by Drug Class for Migraine in 2020 and 2030
Figure 25: Sales Forecast by Class for Migraine in the US in 2020 and 2030
Figure 26: Sales Forecast by Class for Migraine in the 5EU in 2020 and 2030
Figure 27: Sales Forecast by Class for Migraine in the Japan in 2020 and 2030
